Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
ViaCyte
Biotech
Vertex buys ViaCyte for $320M, clearing out T1D competition
Vertex is absorbing ViaCyte for $320 million, taking a bulldozer to the competition of another stem cell-based treatment for diabetes.
Max Bayer
Jul 11, 2022 11:45am
AltruBio snags new CMO with pivot to immunology—Chutes & Ladders
Sep 17, 2021 9:30am
ViaCyte staffs up CSO role to drive diabetes treatments
Sep 13, 2021 1:00pm
ViaCyte scores $45M for type 1 diabetes drugs in midstage trials
Jun 9, 2021 2:47pm
ViaCyte bags $80M to trial diabetes stem cell therapies
Nov 29, 2018 8:11am
CRISPR, ViaCyte team up on gene-edited diabetes treatment
Sep 17, 2018 11:12am
